{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:22:57Z","timestamp":1785522177173,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272743"],"award-info":[{"award-number":["82272743"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172812"],"award-info":[{"award-number":["82172812"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012496"],"award-info":[{"award-number":["2021A1515012496"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012321"],"award-info":[{"award-number":["2022A1515012321"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Enterprise United Foundation of Guangdong Province","award":["2021A1515220182"],"award-info":[{"award-number":["2021A1515220182"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13402-024-00927-9","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:02:52Z","timestamp":1708700572000},"page":"1277-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma"],"prefix":"10.1007","volume":"47","author":[{"given":"Tingyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhang","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"927_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","volume":"67","author":"B. Shuch","year":"2015","unstructured":"B. Shuch, A. Amin, A.J. Armstrong, J.N. Eble, V. Ficarra, A. Lopez-Beltran et al., Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Europ. Urol. 67, 85\u201397 (2015). https:\/\/doi.org\/10.1016\/j.eururo.2014.04.029","journal-title":"Europ. Urol."},{"key":"927_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","volume":"23","author":"J.S. Lam","year":"2005","unstructured":"J.S. Lam, J.T. Leppert, A.S. Belldegrun, R.A. Figlin, Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 23, 202\u2013212 (2005). https:\/\/doi.org\/10.1007\/s00345-004-0466-0","journal-title":"World J. Urol."},{"key":"927_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s0094-0143(03)00056-9","volume":"30","author":"N.K. Janzen","year":"2003","unstructured":"N.K. Janzen, H.L. Kim, R.A. Figlin, A.S. Belldegrun, Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urologic Clini. North Am. 30, 843\u2013852 (2003). https:\/\/doi.org\/10.1016\/s0094-0143(03)00056-9","journal-title":"Urologic Clini. North Am."},{"key":"927_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","volume":"50","author":"A.M. Molina","year":"2014","unstructured":"A.M. Molina, X. Lin, B. Korytowsky, E. Matczak, M.J. Lechuga, R. Wiltshire et al., Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 50, 351\u2013358 (2014). https:\/\/doi.org\/10.1016\/j.ejca.2013.08.021","journal-title":"Eur. J. Cancer"},{"key":"927_CR5","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S. Bracarda","year":"2015","unstructured":"S. Bracarda, R. Iacovelli, L. Boni, M. Rizzo, L. Derosa, M. Rossi et al., Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann. Oncol. 26, 2107\u20132113 (2015). https:\/\/doi.org\/10.1093\/annonc\/mdv315","journal-title":"Ann. Oncol."},{"key":"927_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s1470-2045(09)70162-7","volume":"10","author":"M.E. Gore","year":"2009","unstructured":"M.E. Gore, C. Szczylik, C. Porta, S. Bracarda, G.A. Bjarnason, S. Oudard et al., Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757\u2013763 (2009). https:\/\/doi.org\/10.1016\/s1470-2045(09)70162-7","journal-title":"Lancet Oncol."},{"key":"927_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"B.E. Houk","year":"2010","unstructured":"B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, R.J. Motzer, Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66, 357\u2013371 (2010). https:\/\/doi.org\/10.1007\/s00280-009-1170-y","journal-title":"Cancer Chemother. Pharmacol."},{"key":"927_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1200\/jco.2008.19.0108","volume":"27","author":"D.R. Feldman","year":"2009","unstructured":"D.R. Feldman, M.S. Baum, M.S. Ginsberg, H. Hassoun, C.D. Flombaum, S. Velasco et al., Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432\u20131439 (2009). https:\/\/doi.org\/10.1200\/jco.2008.19.0108","journal-title":"J. Clin. Oncol."},{"key":"927_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","volume":"7","author":"P.H. Patel","year":"2009","unstructured":"P.H. Patel, P.L. Senico, R.E. Curiel, R.J. Motzer, Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourinary Cancer 7, 24\u201327 (2009). https:\/\/doi.org\/10.3816\/CGC.2009.n.004","journal-title":"Clin. Genitourinary Cancer"},{"key":"927_CR10","doi-asserted-by":"publisher","unstructured":"A. Amin, E.R. Plimack, M.S. Ernstoff, L.D. Lewis, T.M. Bauer, D.F. McDermott et al., Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J. Immunother. Cancer 6 (2018). https:\/\/doi.org\/10.1186\/s40425-018-0420-0","DOI":"10.1186\/s40425-018-0420-0"},{"key":"927_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/jci84386","volume":"127","author":"M. Elgendy","year":"2017","unstructured":"M. Elgendy, A.K. Abdel-Aziz, S.L. Renne, V. Bornaghi, G. Procopio, M. Colecchia et al., Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J. Clin. Investig. 127, 153\u2013168 (2017). https:\/\/doi.org\/10.1172\/jci84386","journal-title":"J. Clin. Investig."},{"key":"927_CR12","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1080\/15548627.2015.1085742","volume":"11","author":"S. Giuliano","year":"2015","unstructured":"S. Giuliano, Y. Cormerais, M. Dufies, R. Grepin, P. Colosetti, A. Belaid et al., Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy 11, 1891\u20131904 (2015). https:\/\/doi.org\/10.1080\/15548627.2015.1085742","journal-title":"Autophagy"},{"key":"927_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/1541-7786.Mcr-16-0132","volume":"15","author":"L. DeVorkin","year":"2017","unstructured":"L. DeVorkin, M. Hattersley, P. Kim, J. Ries, J. Spowart, M.S. Anglesio et al., Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol. Cancer Res. 15, 250\u2013258 (2017). https:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0132","journal-title":"Mol. Cancer Res."},{"key":"927_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1254\/jphs.12158FP","volume":"121","author":"T. Ikeda","year":"2013","unstructured":"T. Ikeda, K. Ishii, Y. Saito, M. Miura, A. Otagiri, Y. Kawakami et al., Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells. J. Pharmacol. Sci. 121, 67\u201373 (2013). https:\/\/doi.org\/10.1254\/jphs.12158FP","journal-title":"J. Pharmacol. Sci."},{"key":"927_CR15","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1158\/1535-7163.Mct-17-0136","volume":"16","author":"T. Wiedmer","year":"2017","unstructured":"T. Wiedmer, A. Blank, S. Pantasis, L. Normand, R. Bill, P. Krebs et al., Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism. Mol. Cancer Ther. 16, 2502\u20132515 (2017). https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0136","journal-title":"Mol. Cancer Ther."},{"key":"927_CR16","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.ccr-11-1667","volume":"17","author":"K.J. Gotink","year":"2011","unstructured":"K.J. Gotink, H.J. Broxterman, M. Labots, R.R. de Haas, H. Dekker, R.J. Honeywell et al., Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 17, 7337\u20137346 (2011). https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-1667","journal-title":"Clin. Cancer Res."},{"key":"927_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molcel.2011.02.009","volume":"42","author":"M. Elgendy","year":"2011","unstructured":"M. Elgendy, C. Sheridan, G. Brumatti, S.J. Martin, Oncogenic ras-induced expression of noxa and beclin-1 promotes autophagic cell death and limits clonogenic survival. Molecular Cell 42, 23\u201335 (2011). https:\/\/doi.org\/10.1016\/j.molcel.2011.02.009","journal-title":"Molecular Cell"},{"key":"927_CR18","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/sj.emboj.7601689","volume":"26","author":"M.C. Maiuri","year":"2007","unstructured":"M.C. Maiuri, G. Le Toumelin, A. Criollo, J.C. Rain, F. Gautier, P. Juin et al., Functional and physical interaction between Bcl-X-L and a BH3-like domain in Beclin-1. EMBO J. 26, 2527\u20132539 (2007). https:\/\/doi.org\/10.1038\/sj.emboj.7601689","journal-title":"EMBO J."},{"key":"927_CR19","doi-asserted-by":"publisher","unstructured":"M. Elgendy, M. Ciro, A.K. Abdel-Aziz, G. Belmonte, R. Dal Zuffo, C. Mercurio et al., Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nat. Commun. 5 (2014). https:\/\/doi.org\/10.1038\/ncomms6637","DOI":"10.1038\/ncomms6637"},{"key":"927_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"J.R. Wisniewski","year":"2009","unstructured":"J.R. Wisniewski, A. Zougman, N. Nagaraj, M. Mann, Universal sample preparation method for proteome analysis. Nature Methods 6, 359\u2013U360 (2009). https:\/\/doi.org\/10.1038\/nmeth.1322","journal-title":"Nature Methods"},{"key":"927_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nprot.2015.134","volume":"11","author":"M. Zarei","year":"2016","unstructured":"M. Zarei, A. Sprenger, M. Rackiewicz, J. Dengjel, Fast and easy phosphopeptide fractionation by combinatorial ERLIC-SCX solid-phase extraction for in-depth phosphoproteome analysis. Nature Protocols 11, 37\u201345 (2016). https:\/\/doi.org\/10.1038\/nprot.2015.134","journal-title":"Nature Protocols"},{"key":"927_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"T.C. Chou","year":"1984","unstructured":"T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984). https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4","journal-title":"Adv. Enzyme Regul."},{"key":"927_CR23","first-page":"146","volume":"25","author":"Z.J. Jin","year":"2004","unstructured":"Z.J. Jin, About the evaluation of drug combination. Acta Pharmacol. Sin. 25, 146\u2013147 (2004)","journal-title":"Acta Pharmacol. Sin."},{"key":"927_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1158\/0008-5472.Can-09-3722","volume":"70","author":"D. Huang","year":"2010","unstructured":"D. Huang, Y. Ding, Y. Li, W.M. Luo, Z.F. Zhang, J. Snider et al., Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70, 1053\u20131062 (2010). https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3722","journal-title":"Cancer Res."},{"key":"927_CR25","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1128\/mcb.00620-06","volume":"27","author":"Q. Ding","year":"2007","unstructured":"Q. Ding, X. He, J.M. Hsu, W. Xia, C.T. Chen, L.Y. Li et al., Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell Biol. 27, 4006\u20134017 (2007). https:\/\/doi.org\/10.1128\/mcb.00620-06","journal-title":"Mol. Cell Biol."},{"key":"927_CR26","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","volume":"23","author":"A.M. Domina","year":"2004","unstructured":"A.M. Domina, J.A. Vrana, M.A. Gregory, S.R. Hann, R.W. Craig, MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23, 5301\u20135315 (2004). https:\/\/doi.org\/10.1038\/sj.onc.1207692","journal-title":"Oncogene"},{"key":"927_CR27","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1038\/cddis.2013.18","volume":"4","author":"W.T. Tai","year":"2013","unstructured":"W.T. Tai, C.W. Shiau, H.L. Chen, C.Y. Liu, C.S. Lin, A.L. Cheng et al., Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 4, e485 (2013). https:\/\/doi.org\/10.1038\/cddis.2013.18","journal-title":"Cell Death Dis."},{"key":"927_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrm3735","volume":"15","author":"G. Marino","year":"2014","unstructured":"G. Marino, M. Niso-Santano, E.H. Baehrecke, G. Kroemer, Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15, 81\u201394 (2014). https:\/\/doi.org\/10.1038\/nrm3735","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"927_CR29","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1080\/15548627.2015.1085742","volume":"11","author":"S. Giuliano","year":"2015","unstructured":"S. Giuliano, Y. Cormerais, M. Dufies, R. Gr\u00e9pin, P. Colosetti, A. Belaid et al., Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy 11, 1891\u20131904 (2015). https:\/\/doi.org\/10.1080\/15548627.2015.1085742","journal-title":"Autophagy"},{"key":"927_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","volume":"17","author":"D.J. Klionsky","year":"2021","unstructured":"D.J. Klionsky, A.K. Abdel-Aziz, S. Abdelfatah, M. Abdellatif, A. Abdoli, S. Abel et al., Guidelines for the use and interpretation of assays for monitoring autophagy (4th edn). Autophagy 17, 1\u2013382 (2021). https:\/\/doi.org\/10.1080\/15548627.2020.1797280","journal-title":"Autophagy"},{"key":"927_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","volume":"20","author":"R.J. Motzer","year":"2022","unstructured":"R.J. Motzer, E. Jonasch, N. Agarwal, A. Alva, M. Baine, K. Beckermann et al., Kidney cancer, version 3.2022. J. Natl. Compr. Cancer Network 20, 71\u201389 (2022). https:\/\/doi.org\/10.6004\/jnccn.2022.0001","journal-title":"J. Natl. Compr. Cancer Network"},{"key":"927_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","volume":"29","author":"L. Qu","year":"2016","unstructured":"L. Qu, J. Ding, C. Chen, Z.J. Wu, B. Liu, Y. Gao et al., Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell 29, 653\u2013668 (2016). https:\/\/doi.org\/10.1016\/j.ccell.2016.03.004","journal-title":"Cancer Cell"},{"key":"927_CR33","doi-asserted-by":"publisher","first-page":"10090","DOI":"10.1158\/0008-5472.Can-10-0489","volume":"70","author":"F. Shojaei","year":"2010","unstructured":"F. Shojaei, J.H. Lee, B.H. Simmons, A. Wong, C.O. Esparza, P.A. Plumlee et al., HGF\/c-met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 70, 10090\u201310100 (2010). https:\/\/doi.org\/10.1158\/0008-5472.Can-10-0489","journal-title":"Cancer Res."},{"key":"927_CR34","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/onc.2015.343","volume":"35","author":"L. Zhou","year":"2016","unstructured":"L. Zhou, X.D. Liu, M. Sun, X. Zhang, P. German, S. Bai et al., Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35, 2687\u20132697 (2016). https:\/\/doi.org\/10.1038\/onc.2015.343","journal-title":"Oncogene"},{"key":"927_CR35","doi-asserted-by":"publisher","unstructured":"T.K. Choueiri, S. Halabi, B.L. Sanford, O. Hahn, M.D. Michaelson, M.K. Walsh et al., Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J. Clin. Oncol. 35, 591 (2017). https:\/\/doi.org\/10.1200\/jco.2016.70.7398","DOI":"10.1200\/jco.2016.70.7398"},{"key":"927_CR36","doi-asserted-by":"publisher","unstructured":"J. Deng, Q. Zhang, L.P. Lv, P. Ma, Y.Y. Zhang, N. Zhao et al., Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma. Sci. Rep. 12 (2022). https:\/\/doi.org\/10.1038\/s41598-022-11050-w","DOI":"10.1038\/s41598-022-11050-w"},{"key":"927_CR37","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/02713683.2019.1584320","volume":"44","author":"Y. Ekim","year":"2019","unstructured":"Y. Ekim, S. Kara, B. Gencer, T. Karaca, Efficacy of sunitinib, sunitinib-hesperetin, and sunitinib-doxycycline combinations on experimentally-induced corneal neovascularization. Curr. Eye Res. 44, 590\u2013598 (2019). https:\/\/doi.org\/10.1080\/02713683.2019.1584320","journal-title":"Curr. Eye Res."},{"key":"927_CR38","doi-asserted-by":"publisher","unstructured":"F. Rossari, F. Minutolo, E. Orciuolo, Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J. Hematol. Oncol. 11 (2018). https:\/\/doi.org\/10.1186\/s13045-018-0624-2","DOI":"10.1186\/s13045-018-0624-2"},{"key":"927_CR39","first-page":"327","volume":"9","author":"D.B. Mendel","year":"2003","unstructured":"D.B. Mendel, A.D. Laird, X.H. Xin, S.G. Louie, J.G. Christensen, G.M. Li et al., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin. Cancer Res. 9, 327\u2013337 (2003)","journal-title":"Clin. Cancer Res."},{"key":"927_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s10147-018-1302-7","volume":"23","author":"S. Takasaki","year":"2018","unstructured":"S. Takasaki, Y. Kawasaki, M. Kikuchi, M. Tanaka, M. Suzuka, A. Noda et al., Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int. J. Clin. Oncol. 23, 936\u2013943 (2018). https:\/\/doi.org\/10.1007\/s10147-018-1302-7","journal-title":"Int. J. Clin. Oncol."},{"key":"927_CR41","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.Ccr-04-2601","volume":"11","author":"M. Golemovic","year":"2005","unstructured":"M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P.W. Manley et al., AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11, 4941\u20134947 (2005). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2601","journal-title":"Clin. Cancer Res."},{"key":"927_CR42","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41418-019-0404-8","volume":"27","author":"F. Strappazzon","year":"2020","unstructured":"F. Strappazzon, A. Di Rita, A. Peschiaroli, P.P. Leoncini, F. Locatelli, G. Melino et al., HUWE1 controls MCL1 stability to unleash AMBRA1-induced mitophagy. Cell Death Differ. 27, 1155\u20131168 (2020). https:\/\/doi.org\/10.1038\/s41418-019-0404-8","journal-title":"Cell Death Differ."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-024-00927-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-00927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T06:36:14Z","timestamp":1723530974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-024-00927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s13402-024-00927-9","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"14 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved by the Sun Yat-Sen University Cancer Center Institutional Animal Care and Usage Committee following the Animal Welfare and Rights in China (Approval number: L102012019040I). All the experiments were conducted in the Laboratory Animal Center of Sun Yat-sen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any potential conflicts to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}